Verastem Oncology is a commercial-stage biopharmaceutical company (NASDAQ: VSTM) developing medicines to improve the lives of patients with cancer, with a focus on RAS/MAPK pathway-driven tumors and hematologic cancers. Lead marketed product is Avmapki Fakzynja Co-Pack (avutometinib + defactinib) for KRAS-mutated recurrent low-grade serous ovarian cancer.
Company Info
Upcoming Milestones & Key Dates
Strategic review of oncology combo following RAMP pancreatic readout
Updated Avmapki Fakzynja commercial launch metrics in LGSOC
Clinical Development Pipeline
Recent News
Following the mid-stage readout, Verastem Oncology has decided to move away from its investigational pancreatic cancer drug combo, instead putting resources behind its KRAS inhibitor pill for solid tumors.
Verastem mulls options on approved asset in pancreatic cancer.
Leadership Team
President & Chief Executive Officer
Careers & Job Openings